SFX by Ex Libris Inc.

Title:	Cooperativity Of RUNX1 and CSF3R Mutations In The Development Of Leukemia In Severe Congenital Neutropenia: A Unique Pathway In Myeloid Leukemogenesis
Source:	Blood [0006-4971] Skokowa, Julia yr:2013

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Latos-BieleÅska, A. "Three novel GJA1 missense substitutions resulting in oculo-dento-digital dysplasia (ODDD) - Further extension of the mutational spectrum." Gene 539.1 (2014): 157-161.
description	2.	Kochenderfer, James N. "Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors." Nature Reviews Clinical Oncology 10.5 (2013): 267-276.
description	3.	Cheadle, Eleanor J. "CAR T cells: driving the road from the laboratory to the clinic." Immunological reviews 257.1, Sp. Iss. SI (2014): 91-106.
description	4.	June, Carl H. "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia." The New England journal of medicine 365.8 (2011): 725-733.
description	5.	Brentjens, Renier J. "CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia." Science translational medicine 5.177 (2013): 177-177.
description	6.	Melenhorst, Bruce J. "Innovation and opportunity for chimeric antigen receptor targeted TÂ cells." Cytotherapy 15.9 (2013): 1046-1053.
description	7.	Lodi, Fábio R. "Expression of connexin-43 in the cardiac muscle of children diagnosed with hypoplastic left heart syndrome: a Western blot and confocal laser scanning microscopy study." Cardiology in the young 30.2 (2019): 1-5.
description	8.	Oehl Jaschkowitz, B. "Deletions in 14q24.1q24.3 are associated with congenital heart defects, brachydactyly, and mild intellectual disability." American journal of medical genetics. Part A 164.3 (2013): 620-626.
description	9.	Traboulsi, Luis A Rassi I. "Oculodentodigital dysplasia: new ocular findings and a novel connexin 43 mutation." Archives of ophthalmology 129.6 (2011): 781-4.
description	10.	Heslop, H E E. "Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes." Nature medicine 2.5: 551-555.
description	11.	Rosenberg, Steven A. "A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response." Clinical cancer research 21.5 (2014): 1019-1027.
description	12.	Kalos, M. "T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia." Science translational medicine 3.95 (2011): 95-95.
description	13.	Abken, H. "Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma." Immunological reviews 257.1 (2014): 83-90.
description	14.	Robbins, Paul F. "Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1." Journal of clinical oncology 29.7 (2011): 917-24.
description	15.	June, Michael L. "Chimeric Antigen Receptor-Modified T Cells in CLL REPLY." The New England journal of medicine 365.20 (2011): 1938-1938.
description	16.	Brentjens, Renier J. "Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias." Blood 118.18 (2011): 4817-28.
description	17.	Loskog, A S I S. "Genetically engineered T cells for the treatment of cancer." Journal of internal medicine 273.2 (2013): 166-181.
description	18.	Curran, Kevin J. "Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions." The journal of gene medicine 14.6 (2012): 405-415.
description	19.	"Driving Ahead with CAR T Cells." Cancer discovery 3.6 (2013): 595-596.
description	20.	Singh, Jagdeep K. "Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-dependent and -independent Mechanisms." Clinical cancer research 19.3 (2012): 643-656.